business / news / / Markets Insider
David Dai from UBS maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$31.00.
UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals with a A$31.00 target.
KEY POINTS
- Telix Pharmaceuticals reported A$630.94 million in revenue but a GAAP net loss of A$7.38 million.
- Last year, Telix had a net profit of A$38.24 million, indicating a shift to a net loss.
- Canaccord Genuity also issued a Buy rating on Telix Pharmaceuticals in a recent report.
COMPANIES
Summarized by Newsio from Markets Insider. How we summarize →